戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                   Therefore, we did not find evidence for a benefit of XTC in the context of first-line failure on this c
2                 The materials presented here have the added benefit of avoiding resource-sensitive transition metals such
3                   Success in this area could have the added benefit of inspiring other fields in medically relevant mater
4 e an effective sorbent for fluoride removal, with the added benefit of re-use of a waste product.
5 selection and random forest importance, with the additional benefit of covariate adjustment and multiple testing correcti
6 ics the behavior of dual-ended readout, with the additional benefit of improved crystal identification.
7       The use of specific captured beads had the additional benefit of stabilizing miR-122 after sample collection, with
8  persistent AR, but additional studies support the additive benefit of combination treatment with INCS and intranasal ant
9              A first field test of NMP indicates safety and benefit of this approach.
10 ntinues to be no high-quality clinical data showing a clear benefit of these agents for this disease.
11                          The potential utility and clinical benefit of hybrid operating theaters are increasingly postula
12                                                The clinical benefit of LDL cholesterol lowering treatment in older patien
13 nd/or dried fruits is highly recommended to obtain the full benefit of the nutrients, bioactives, and antioxidants that t
14                                              The functional benefit of cardiac cell therapy is thus due to an acute infla
15 first HHF was consistent across most subgroups, but greater benefit of ertugliflozin was observed in 3 populations: basel
16 prevented under the cleaning bundle returned a net monetary benefit of AUD$1.02 million and an incremental cost-effective
17 ough to death), and result in a health-related net monetary benefit of pound 7.4 billion (95% UI pound 2.0 billion-pound
18 adjunctive hydrocortisone therapy showed a 90-day monetized benefit of $25,539 per patient (95% CI, $22,853-$28,224), dri
19 alysis using the reported median showed a greater monetized benefit of $10,658 (Adjunctive Corticosteroid Treatment in Cr
20 ments, COM seems (1) more accurate in capturing the overall benefit of the regenerative procedure and (2) to better ident
21 controlled Vitamin D and Omega-3 Trial suggested a possible benefit of vitamin D on cancer incidence among black individu
22                                         Despite a potential benefit of PAH treatment, prognosis remains poor, and double-
23 in situ (DCIS) for ER is recommended to determine potential benefit of endocrine therapies to reduce risk of future breas
24                                    We discuss the potential benefit of concurrent administration of OT and naloxone (NAL)
25                          Our results quantify the potential benefit of decreasing obesity among at-risk women.
26  of CM following S. aureus IMI and highlights the potential benefit of diagnostics tools to identify S. aureus CC during
27                    The results also highlight the potential benefit of neurofeedback training in facilitating voluntary s
28 bly between pancreatic centers, demonstrating the potential benefit of quality assurance programs.
29                                         However, a survival benefit of CRT in this population has not been established.
30                                     We observed no survival benefit of ECD transplants vs remaining on the waitlist (aHR
31                                To characterize the survival benefit of accepting DCD50 kidneys, we used 2010-2018 Scienti
32 r After Primary Angioplasty) aimed to evaluate the survival benefit of prophylactic implantable cardioverter defibrillato
33 -cross-reactive antigen by tumors correlated with long-term benefit of PD-1 blockade therapy.
34 uggest that combined CXCR4 and PD-1 blockade may expand the benefit of chemotherapy in PDAC and warrants confirmation in
35 uld be treated as a form of public good, to be used for the benefit of future patients.
36        Effectors alter host metabolism and immunity for the benefit of pathogens.
37 zing the return on investment: scientific knowledge for the benefit of patients and society.
38             Corrective actions should be undertaken for the benefit of the Health System.
39                                Reducing size could have the benefit of reducing potential immunogenicity problems.
40 h-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy (C
41                                    However, the size of the benefit of earlier initiation of treatment and the overall co
42  indistinguishable from medium mass resolution offering the benefit of increased sensitivity and versatility of this meth
43 (+)]) deposition have, otherwise, increased, offsetting the benefit of reduction in NO(y) deposition.
44           In addition, each section includes details on the benefit of the IDAs and perceived limitations for each system
45 on integrated genetic profiles that are able to predict the benefit of GO on outcome.
46 do not allow for any conclusion to be reached regarding the benefit of one formula over another formula intended for CMA
47                       Because several studies regarding the benefit of PACs are ambiguous, the use of PACs is variable am
48 s is linked with larger genomes and we demonstrate that the benefit of LGT declines rapidly with genome size.
49                                       While the therapeutic benefit of monoclonal antibodies against infectious disease a
50 risk and delivers hypothesis-generating data on the varying benefit of increasing physical activity and improving diet on